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A B S T R A C T
Background
Cystic fibrosis (CF) is the most common, life-limiting, genetically inherited disease. It aFects multiple organs, particularly the respiratory
system. However, gastrointestinal problems such as constipation and distal intestinal obstruction syndrome (DIOS) are also important and
well-recognised complications in CF. They share similar symptoms e.g. bloating, abdominal pain, but are distinct conditions. Constipation
occurs when there is gradual faecal impaction of the colon, but DIOS occurs when there is an accumulation of faeces and sticky mucus,
forming a mass in the distal part of the small intestine. The mass may partially block the intestine (incomplete DIOS) or completely block
the intestine (complete DIOS). Symptoms of DIOS can aFect quality of life and other aspects of CF health, such as airway clearance, exercise,
sleep and nutritional status. Treatment of constipation and prevention of complete bowel obstruction are required for gastrointestinal
management in CF. However, many diFerent strategies are used in clinical practice and there is a lack of consensus. The importance of this
topic was highlighted in a recent research priority setting exercise by the James Lind Alliance.
Objectives
To evaluate the eFectiveness and safety of laxative agents of diFering types for preventing DIOS (complete and incomplete) in children
and adults with CF.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from
comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date
of search: 22 May 2018.
We also searched online trial registries. Date of last search: 10 June 2018.
Selection criteria
Randomised and quasi-randomised controlled parallel trials comparing laxative therapy for preventing DIOS (including osmotic agents,
stimulants, mucolytics and substances with more than one action) at any dose to placebo, no treatment or an alternative laxative therapy,
in people of any age with pancreatic suFicient or insuFicient CF and any stage of lung disease. Randomised cross-over trials were judged
on an individual basis.
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Data collection and analysis
Two authors independently assessed trials for inclusion, extracted outcome data and performed a risk of bias assessment for the included
data. We judged the quality of the evidence using GRADE criteria.
Main results
We included one cross-over trial (17 participants) with a duration of 12 months, in which participants were randomly allocated to either
cisapride (a gastro-prokinetic agent) or placebo for six months each. The trial had an unclear risk of bias for most domains but had a high
risk of reporting bias.
Radiograph scores revealed no diFerence in occurrence of DIOS between cisapride and placebo (narrative report, no data provided). There
were no adverse eFects. Symptom scores were the only secondary outcome within the review that were reported. Total gastrointestinal
symptom scores favoured cisapride with a statistically significant mean diFerence (MD) of -7.60 (95% confidence interval (CI) -14.73 to
-0.47). There was no significant diFerence at six months between cisapride and placebo for abdominal distension, MD -0.90 (95% CI -2.39 to
0.59) or abdominal pain, MD -0.4 (95% CI -2.05 to 1.25). The global symptom scores (whether individuals felt better or worse) were reported
in the paper to favour cisapride and be statistically significant (P < 0.05).
We assessed the available data to be very low quality. There was a great deal of missing data from the included trial and the investigators
failed to report numerical data for many outcomes. The overall risk of bias of the trial was unclear and it had a high risk for reporting bias.
There was also indirectness; the trial drug (cisapride) has since been removed from the market in several countries due to adverse eFects,
thus it has no current applicability for preventing DIOS. The included trial also had very few participants, which downgraded the quality
a further level for precision.
Authors' conclusions
There is an absence of evidence for interventions for the prevention of DIOS. As there was only one included trial, we could not perform
a meta-analysis of the data. Furthermore, the included trial compared a prokinetic agent (cisapride) that is no longer licensed for use in
a number of countries due to the risk of serious cardiac events, a finding that came to light aNer the trial was conducted. Therefore, the
limited findings from the trial are not applicable in current clinical practice.
Overall, a great deal more research needs to be undertaken on gastrointestinal complications in CF, as this is a very poorly studied area
compared to respiratory complications in CF.
P L A I N   L A N G U A G E   S U M M A R Y
Which interventions are e5ective and safe for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis?
Background
Cystic fibrosis (CF) is an inherited, life-long condition that causes organ systems in the body to produce large amounts of thick and sticky
mucus. The most commonly aFected area is the lungs, in which thick mucus leads to recurrent chest infections and breathing diFiculties.
Another commonly aFected area is the digestive system. Many people with CF suFer from bloating and abdominal pain which may be
caused by constipation or distal intestinal obstruction syndrome (DIOS). In DIOS, overproduction of thick mucus combines with stool and
sticks to the intestinal wall. This mass can partially block the intestine (incomplete DIOS) or completely block the intestine (complete DIOS).
The latter causes severe pain, vomiting and is treated as a medical emergency. As part of eFective care for people with CF, constipation
should therefore be treated and complete bowel obstruction be prevented. It is also important to recognise that constipation and DIOS
impact on other aspects of CF health. Bloating, abdominal pain and nausea may aFect airway clearance, exercise and sleep. Nutritional
status may also be aFected due to decreased appetite and malabsorption. DIOS may aFect the absorption of other medications taken by
people with CF. Overall, DIOS can significantly impair quality of life. DiFerent laxatives are currently used in clinics, but prescribing practices
diFer and there is no consensus on optimal treatment strategies. Hence, this review aimed to analyse the evidence for the preventing DIOS.
Search date
We last searched for evidence: 10 June 2018.
Trial characteristics
We included one trial in the review, which included 17 people aged between 13 to 35 years. These people were randomly put into groups
to take either a placebo drug (with no active medication) or cisapride for six months each and then to cross over and take the alternative
treatment for a further six months.
Key results
The trial used radiography to diagnose DIOS, but did not provide any data and only stated that there was no diFerence between cisapride
and placebo. The trial also stated that there were no adverse eFects from the cisapride. The trial assessed participant-reported total and
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individual gastrointestinal symptom scores. People in the cisapride group reported an improvement in total gastrointestinal symptom
scores compared to those in the placebo group. However, there were no diFerences reported between groups for the individual symptom
scores of abdominal pain and abdominal distension (swelling). Participants also reported global symptom scores, which showed that most
people felt better taking cisapride compared to placebo.
Quality of the evidence
The overall quality of the evidence was very low. With one trial in this review, we could not combine data from diFerent trials. The trial
did not provide enough information about the methods used for allocating participants or about missing data and did not fully report
certain results. The small number of participants also lowered the precision of the results. Since this trial was conducted, cisapride has
been removed from the market in a number of countries due to rare but serious heart complications, therefore it has no applicability to
current clinical practice.
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Summary of findings for the main comparison.   Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic
fibrosis
Cisapride compared to placebo for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis
Patient or population: preventing DIOS in cystic fibrosis
Setting: tertiary Centre
Intervention: cisapride
Comparison: placebo
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo Risk with cisapride
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of
the evidence
(GRADE)
Comments
Radiological diag-
nosis of DIOS (physi-
cian-measured radio-
logical scores)
Follow-up: baseline to
6 months
Trial investigators stated that there was no signifi-
cant difference between cisapride and placebo.
NA 17
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2 3
Radiologist scored for radiograph-
ic signs of DIOS, no numerical data
available.
Adverse effects (partic-
ipant interviews)
Follow-up: 3 to 12
months
No adverse effects were noted in either group. NA 17
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 3 4
No numerical data available.
Total gastrointesti-
nal symptom scores
(participant-reported
symptom scores from
20 to 100)
Follow-up: 3 to 12
months
The mean difference was 7.6 lower in the cisapride
arm
(14.73 lower to 0.47 lower) than when the same par-
ticipants took a placebo.
NA 17
(1 RCT)
⊕⊝⊝⊝
VERY LOW 2 3 4
Score made up of 10 different gas-
trointestinal symptoms: heartburn,
flatulence, regurgitation, fullness,
abdominal distension, abdominal
pain, diarrhoea, nausea, vomiting,
anorexia.
Hospitalisation for any
cause
Outcome not reported. NA NA  
Hospitalisation for
DIOS
Outcome not reported. NA NA  
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Quality of life Outcome not reported. NA NA  
Tolerability Outcome not reported. NA NA  
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DIOS: distal intestinal obstruction syndrome; NA: not applicable; RCT: randomised controlled trial.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
1. Selective reporting may have occurred with this outcome; allocation concealment and sequence generation was unclear.
2. Cisapride is a prokinetic, not a typical laxative agent (diFerent to protocol). The study was conducted in 1990 when cisapride was still prescribed. It has now been taken oF the
UK market and other international markets due to its rare but serious cardiac eFects.
3. Very small number of participants in the trial does not give suFicient information to give a precise eFect estimate.
4. Allocation concealment and sequence generation ranked as unclear risk of bias.
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B A C K G R O U N D
Cystic fibrosis (CF) is an important genetic disorder. It is life-limiting
and aFected individuals have dysfunction of several organ systems
which results in morbidity and reduced quality of life (QoL). To
be aFected a person must possess two faulty copies of the gene
that encodes a protein called the cystic fibrosis transmembrane
conductance regulator (CFTR). About one in 25 of the UK white
population carry a single faulty copy of this gene and one in 2500
newborns in the UK are born with CF (Tobias 2011). Worldwide
the condition aFects approximately 70,000 children and adults (CF
Foundation 2016).
Although respiratory symptoms are prominent, and oNen the
focus of clinical care, CF is a multifaceted disease which also has
important eFects on the gastrointestinal and endocrine systems.
EFective management of CF is made more challenging by the fact
that problems in any of these systems can interact in an adverse
way. The CFTR is expressed in many cell types throughout the body;
it regulates chloride transport and thus indirectly influences water
transport across the cell membranes. Absent or dysfunctional CFTR
leads to thickened, dehydrated mucus.
Description of the condition
Distal intestinal obstruction syndrome (DIOS) is a well-recognised
morbidity in CF. It is the result of the accumulation of thick
and sticky material within the bowel (both mucus and faeces)
particularly in the final part of the small intestine (the terminal
ileum and caecum). This mass becomes connected to the bowel
wall itself and the finger-like projections of the small bowel
(intestinal villi) making it fixed in position and diFicult to remove
(Colombo 2011). The bowel may be completely blocked (complete
DIOS) or only partially blocked (incomplete DIOS), e.g. when a
persistent mass is found low down on the right-hand side (right iliac
fossa). Previously DIOS was known as meconium ileus equivalent
(MIE), and aFects between 10% to 22% of individuals with CF
(Davidson 1987; Dray 2004; Penketh 1987; Rubinstein 1986). It
aFects adults more than children; the estimated prevalence of
DIOS is between 5 and 12 episodes per 1000 patient years for
children, but 35.5 per 1000 patient years for adults (Anderson 1990;
Colombo 2011; Houwen 2010). Once an individual has had DIOS
the recurrence risk is approximately 50% (Dray 2004). A number
of factors contribute to the occurrence of DIOS. It occurs more
commonly in individuals who have pancreatic enzyme deficiency
(Munck 2016); less than 10% of individuals with DIOS are pancreatic
suFicient (Houwen 2010). Anecdotally, it is also more common
in those who do not adhere to pancreatic enzyme replacement
therapy. Meconium ileus (a type of bowel obstruction occurring
shortly aNer birth) is another recognised risk factor, with up to 50%
of those with DIOS having been aFected by this (Houwen 2010).
The incidence of DIOS may also be increased aNer transplantation
surgery and can be as high as 20% (Gilljam 2003; Millar-Jones 1995).
In part, it occurs due to the loss of CFTR function in the intestine,
where CFTR regulates chloride, bicarbonate and sodium transport.
Distinguishing DIOS from other causes of bowel obstruction in
CF
The CF gut is prone to obstruction from other causes due to
its altered pathophysiology (Van der Doef 2011). A small but
significant proportion of newborns with CF present either at birth
or shortly aNerwards with bowel obstruction - meconium ileus.
Meconium ileus occurs in 13% to 17% of the CF population
(Van der Doef 2011). Throughout life, children and adults with
CF are prone to constipation, with almost half of all children
studied (47%) having evidence of constipation (Van der Doef 2010).
However, it is possible to distinguish between constipation and
DIOS both clinically and radiologically. One widely-used definition
of DIOS is an acute complete or incomplete faecal obstruction in
the ileocecum; whereas constipation is defined as gradual faecal
impaction of the total colon (Houwen 2010). Individuals are more
likely to describe an exact time when their symptoms started
in the acute picture of DIOS, but will describe a more chronic
build up of symptoms in constipation. It is therefore important
to rule out other surgical diagnoses when considering DIOS, such
as intussusception, volvulus and strangulated hernia. Using this
definition of DIOS in individuals under 18 years of age, 51 episodes
in 39 individuals were recorded, giving an overall incidence of 6.2
(95% confidence interval (CI) 4.4 to 7.9) episodes per 1000 patient-
years. Although there is undoubtedly overlap between constipation
and incomplete DIOS, the clinical definition proposed by Houwen
permits the eFectiveness of treatments to be monitored clinically
(Houwen 2010). It is worth noting that prior to this definition of
DIOS (incomplete versus complete) in 2010, studies may not have
accurately reported the incidence of DIOS due to to some episodes
of constipation being considered as incomplete DIOS. In this light,
one should consider that although previous studies have estimated
diFerent incidences for DIOS between children and adults, Munck
found similar incidences between these two groups in a more
recent study (Munck 2016).
Description of the intervention
Treatment of constipation and the prevention of complete bowel
obstruction is required as part of optimal care for individuals with
CF. DIOS is predominantly an ileocaecal pathology (Houwen 2010).
Many strategies are currently used in clinical practice and there is
a lack of consensus about what the best preventative measures
are likely to be. In addition to ensuring adequate hydration and
adherence with pancreatic enzyme supplementation, diFerent
centres use diFerent combinations of laxatives to prevent DIOS
including lactulose, senna, polyethylene glycol (e.g. Movicol®),
sodium docusate, sodium picosulphate and fibre.
Although most children and adults with CF are prescribed
interventions to prevent DIOS at some stage, there is significant
heterogeneity observed between clinicians in their choices of
agent. With the advent of newer laxative agents, e.g. Movicol®, some
centres have changed their approach.
This review focuses upon the use of laxative agents (aperients) for
preventing DIOS. There are three main groups of laxatives based
upon their primary mechanism of action (although there is overlap
between the mechanism of action for some agents). Aside from the
main groups of laxative, prokinetic agents may also prevent DIOS,
although these are less commonly used in clinical practice (post hoc
change).
1. Osmotic laxatives
Osmotic laxatives are faecal soNeners which work by increasing
water in the large bowel, either by drawing fluid from the body into
the bowel or by retaining the fluid they were administered with.
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (Review)
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Lactulose
Lactulose is given orally; it is widely used, but may cause flatulence
or abdominal pain in high doses (Colombo 2011).
Macrogol 3350
Macrogol 3350 is also known as polyethylene glycol, or under
the brand names Movicol®, Laxido® or Klean-Prep®. Movicol® is
recommended as first-line treatment for constipation (NICE 2015).
It is commonly given to children for chronic constipation or at a
higher dose in faecal impaction. It can be given as an oral solution or
powder (BNFc 2016). Laxido® is a very similar product which is also
recommended for treatment of chronic constipation or impaction.
Klean-Prep® can also be used, with the aim to cleanse the bowel.
The solution is given until clear fluid is passed per rectum. As
larger volumes are required, it is oNen necessary to administer via
gastrostomy or nasogastric tube (Colombo 2011; NICE 2015).
Diatrizoate
Oral diatrizoate (also known as Gastrografin®) is used by many
centres to treat DIOS. It is given as a single dose, which can be
repeated aNer 24 hours. Rectal diatrizoate can also be used in more
severe cases (Colombo 2011). As diatrizoate is highly osmotic, the
individual must be adequately hydrated prior to administration in
order to avoid complications such as shock and perforation of the
bowel (Tuldahar 1999).
2. Stimulant laxatives
Senna
Senna acts by stimulating peristalsis and increases the emptying of
the bowel. Senna is therefore useful when the individual has soN
stools, but finds it diFicult to pass them (NICE 2015).
Sodium docusate
Sodium docusate acts both as a stimulant and also as a stool
soNener. It can be administered orally, but if this does not relieve
faecal impaction, the drug can also be given as an enema (NICE
2015).
Sodium picosulphate
Sodium picosulphate acts by stimulating the mucosa of the large
bowel, increasing its motility; it is given as an oral solution (BNFc
2016).
3. Mucolytics
Oral N-acetylcysteine
N-acetylcysteine (also known as Parvolex®) is indicated for
abnormal or impaired mucus production. It can be given as a single
oral dose for treatment of meconium ileus or DIOS. It is typically
diluted in a sweet drink, such as orange juice or cola, to mask the
strong and bitter taste (BNFc 2016).
4. Prokinetics
Aside from the main groups of laxatives already mentioned,
we assessed the evidence for prokinetic agents in preventing
DIOS (post hoc change). These agents work by increasing the
co-ordination of gut wall contractions and motility, enhancing
the displacement of bowel contents (Tonni 1996). Examples
of prokinetic agents include erythromycin, metoclopramide,
cisapride, renzapride, domperidone and octreotide. Three
prokinetic agents (prucalopride, linaclotide and lubiprostone)
are specifically recommended in the UK by NICE guidelines for
refractory constipation syndromes (NICE 2017).
How the intervention might work
DiFerent aperients have diFerent mechanisms of action.
Historically these have been divided into the broad categories
described above. In clinical practice it has been helpful to titrate
the doses of these to achieve a reduction in abdominal pains and
a normal physical examination, e.g. resolution of right iliac fossa
mass. Some newer agents (e.g. Movicol®) combine these eFects
providing both soNening and stimulation.
For preventing DIOS, laxatives are likely to work by increasing
stool volume and reducing gut transit time or by soNening
mucofaeculant material that has built up in the gut. The
passage of larger volumes of more liquid stool may have a
mechanical eFect on any adherent mucofaeces. However, the use
of high doses of laxatives are likely to lead to other undesirable
consequences including the unacceptable frequency of stooling,
soiling, abdominal distension, flatulence and abdominal pain.
Why it is important to do this review
Intestinal obstruction is an important and common problem in CF
as highlighted by the recent research priority setting partnership
with the James Lind Alliance (Rowbotham 2017). Incomplete
DIOS is relatively common and there is considerable variation in
practice. In our clinical experience, prophylaxis for DIOS is given to
individuals who have had an episode of complete DIOS, those who
have clinical signs consistent with incomplete DIOS or those with
pancreatic insuFiciency and clinical or radiological manifestations
of constipation (e.g. faecal masses palpable on clinical examination
or reported abdominal pain). The evidence base for this practice
is unclear and there is no clear evidence base for any preventative
therapies for DIOS (Colombo 2011).
Individuals with CF undergo a very large treatment burden. In
discussing the risks and benefits of preventative treatment for DIOS
it is important that we give clear information about the likely side
eFects and tolerability of any proposed therapy.
O B J E C T I V E S
To evaluate the eFectiveness and safety of laxative agents of
diFering types for preventing DIOS (complete and incomplete) in
children and adults with CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We have included randomised controlled trials (RCTs) and quasi-
RCTs of parallel design. We assessed quasi-RCTs on their merit using
the Cochrane risk of bias tool and if review authors were satisfied
that the groups were similar at baseline, we included them.
We also assessed cross-over trials for possible inclusion on an
individual basis. If we deemed the treatment to alter the condition
to the extent that, on entry to subsequent phases, the participants
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diFer from their initial state, we excluded the trial unless we could
use data from the first phase only (see Unit of analysis issues).
Types of participants
Children and adults with CF diagnosed by sweat test or genetic
testing, with all stages and severity of lung disease and with or
without pancreatic suFiciency.
Types of interventions
We compared the diFerent treatment groups of enteral laxative
therapy for preventing DIOS (including osmotic agents, stimulants,
mucolytics, substances which have more than one action and
prokinetic agents (post hoc change)) at any dose to placebo, no
treatment or an alternative oral laxative therapy.
As some treatments have significant overlap in their mechanisms of
action (e.g. Movicol® is a osmotic agent which also has a stimulant
eFect), we planned to initially examine whether any preventative
treatment is eFective and then to examine the relative eFectiveness
of diFerent classes of agents as a subgroup analysis.
Types of outcome measures
Primary outcomes
1. Complete or incomplete DIOS diagnosed with a clinical (e.g.
right iliac fossa or distension or pain) and radiological (e.g. small
intestinal dilated bowel or faecal mass) combination
2. Adverse eFects from treatment
a. serious adverse eFects of treatment regimens (including,
but not limited to, rectal bleeding, intestinal perforation,
mucosal erosions, anaphylactic reaction, vomiting with
electrolyte disturbance)
b. other adverse eFects of treatment (e.g. diarrhoea or soiling,
abdominal distension, loss of continence or pain)
Secondary outcomes
1. Time to hospital admission
a. all causes
b. due to DIOS
2. Participant-reported QoL scores
3. Participant-reported symptom scores
4. Tolerability (participant- or investigator-reported rates of
concordance)
Search methods for identification of studies
We searched for all relevant published and unpublished trials
without restrictions on language, year or publication status.
Electronic searches
We identified relevant studies from the Group's Cystic Fibrosis Trials
Register using the terms: distal intestinal obstruction syndrome
[DIOS].
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of the Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis
conferences: the International Cystic Fibrosis Conference; the
European Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group website.
Date of last search: 22 May 2018.
We searched the following databases between 09 May 2018 and 10
June 2018:
• Cochrane Central Register of Controlled Trials (CENTRAL; 2017,
Issue 12) in the Cochrane Library (www.thecochranelibrary.com)
(searched 09 May 2018);• MEDLINE Ovid (1946 to 09 May 2018);• Embase Ovid (1974 to 10 June 2018).
We also searched the following trials registries and other resources
between 09 May 2018 and 16 May 2018:
• US National Institutes of Health Ongoing Trials Register
Clinicaltrials.gov (www.clinicaltrials.gov; searched 16 May
2018);• International Standard Randomised Controlled Trial Number
(ISRCTN) Registry (www.isrctn.com; searched 09 May 2018);• World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch; searched 16
May 2018);• Open Grey (www.opengrey.eu/; searched 09 May 2018).
For details of our search strategies, please see the appendices
(Appendix 1).
Searching other resources
We checked the bibliographies of included trials and any relevant
systematic reviews identified for further references to relevant
trials.
Data collection and analysis
Selection of studies
Once we had the complete list of identified references, one author
(JG) checked for and removed any duplicates. Two authors (WC and
JG) then reviewed all titles and abstracts and discarded references
which clearly did not meet the inclusion criteria. We attempted to
resolve any disagreements by discussion, but if we could not reach
a decision, we asked the third author (FG) of the review to mediate
until we reached a final decision. Once we discarded trials on the
basis of title and abstract, we obtained full copies of the remaining
references and screened these using a standardised screening form
customised for this review.
We considered trials in any language and translated them as
necessary. We included trials published as full texts, but if there
was only an abstract available, we included it if it presented results.
If there were no results available within the abstract or on any
trials registry sites, then we classified the trial as 'Studies awaiting
assessment' until more information is available. Similarly with
unpublished trials, if a trial met our inclusion criteria and quality
assessment then we included it.
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We presented the results of the search using a standardised flow
chart (Figure 1).
 
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram (Moher 2009)
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Figure 1.   (Continued)
 
Data extraction and management
Two authors (WC and JG) independently extracted data using a
specially designed data extraction form developed by the Cochrane
Cystic Fibrosis and Genetic Disorders Review Group and adapted to
this review. We collected data on:
• participant characteristics;• trial characteristics and trial design;• intervention and comparator;• outcome data - we will report data for each outcome separately.
One author (WC) checked the independent data extraction forms
for discrepancies and if there were any which we could not resolve
by discussion, a third author (FG) arbitrated.
We entered the extracted data into the Review Manager soNware
for analysis (RevMan 2014). We planned to initially carry out
a comparison of any laxative agent versus placebo or usual
treatment and then, if possible, undertake a subgroup analysis
by type of laxative (see Subgroup analysis and investigation of
heterogeneity), but we did not do this as we only included one trial
in the review.
Assessment of risk of bias in included studies
We used the risk of bias tool as described in the Cochrane Handbook
for Systematic Reviews of Interventions to assess the risk of bias
across six domains (sequence generation, allocation concealment,
blinding, incomplete outcome data, selective reporting and other
potential sources of bias) (Higgins 2011).
We planned that if the trial described the methods of
randomisation and allocation, including the concealment of the
allocation sequence from the researchers, and we deemed these to
be adequate, then we would rank the trial as having a low risk of
bias for this domain. Where these were inadequate, we would rank
the trial as being at a high risk and where it was unclear from the
description given, then we would rank it as having an unclear risk
of bias.
Similarly for blinding, we looked at the method used and who was
blinded to determine the risk of bias.
We planned to extract information on missing data and how the
investigators recorded participant withdrawals and loss to follow-
up. We also planned to look at whether missing data were equally
distributed between the intervention and control groups. If all
review authors agreed that missing data had been accounted for
adequately, then we would judge the trial to be at a low risk of
bias. We would record the trial as having a high risk of bias if
investigators did not adequately report the missing data and would
record it as having an unclear risk of bias if we were unable to see
how the missing data had been reported. Two authors assessed
the included trial to determine whether the investigators used an
intention-to-treat (ITT) analysis and again, once we reached an
agreement, we determined the risk of bias as being high, low or
unclear.
We planned that if the trial investigators reported all outcomes
in the paper, we would record a low risk of bias from selective
reporting. If the paper stated that investigators measured
outcomes, but they did not report the results of these, we would
rank the paper as being at high risk. If it was unclear to us whether
the trial reported all outcomes measured, then we would state this
and rank it as unclear for this domain. We planned to search for trial
protocols to be able to assess outcome reporting. If we could not
locate the protocol, we planned to assess outcome reporting based
on a comparison between the methods section of the full published
paper and the results section. As we could not locate the protocol of
the included trial, this is how we assessed potential reporting bias.
The review authors looked for any other potential sources of bias in
the included trial and recorded what they found. According to these
findings, if neither author had found any other source of bias, then
we would rank the trial as having a low risk for this domain and high
risk if the opposite was true.
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We presented the results of the risk of bias assessment both
individually and in a summary table.
Measures of treatment e5ect
For dichotomous data (complete DIOS, incomplete DIOS, pooled
adverse eFects, failure to tolerate treatment and adherence), we
planned to calculate a pooled estimate of the treatment eFects
for each outcome across trials using the risk ratio (RR) and
95% confidence intervals (CIs) where appropriate. For individual
adverse events, e.g. reported soiling, we planned to report 99% CIs.
For continuous data (participant-reported QoL, symptom scores)
we planned to record the mean change and standard deviation
(SD) from baseline for each group. We intended to calculate a
pooled estimate of treatment eFect using the mean diFerence (MD)
and 95% CIs. Where trials used diFerent units of measurement
or measurement scales for reporting the same outcome (which
is likely to be true for QoL and symptom scores) we planned to
use the standardised mean diFerence (SMD) to report the results.
Where trials only reported a pre-intervention mean (SD) and post-
intervention mean (SD) then we planned to calculate the mean
change but not the SD of the change. We would report these results
narratively. For the included trial we used the generic inverse
variance method to generate a MD and corresponding 95% CIs due
to limitations of the available data.
For time-to-event data (e.g. time to hospitalisation) we intended to
express the intervention eFect as a hazard ratio (HR) with 95% CIs
using the generic inverse variance method.
Where end-points are semantically diFerent but report similar
outcomes then we planned to group outcomes. Thus, synonymous
terms are considered jointly. We considered:
• abdominal distension (reported) to be synonymous with
bloating, swelling or gaseous distension;• pain to be synonymous with discomfort or ache;• vomiting to be synonymous with emesis;• constipation to be synonymous with straining or dyschezia.
Unit of analysis issues
We assessed the included trial, which is of cross-over design, to
establish how much data we could include in the analysis. We
planned that where the authors had taken account of the cross-
over design in the analysis, any carry-over eFect and within-person
diFerences, we would be able to include the trial. Where the data
had not been analysed appropriately, we may have been able to
include data from the first phase of the cross-over trial as if it were
a parallel design; although the advantage of the cross-over design
(using participants as their own controls) would be lost (Elbourne
2002). We were able to include both phases of the trial, as the
authors accounted for the carry-over treatment eFect and analysed
the data whilst taking into account the cross-over design.
If we had found multi-arm trials which fall into more than one
comparison, and where the two active treatment arms are diFerent
types of laxative regimen, e.g. Movicol® versus lactulose and
senna versus placebo, we planned to analyse each treatment arm
separately against placebo and where appropriate include results
in a meta-analysis. If the two active treatment arms had been of
the same type of laxative (e.g. soNening agents), but employed a
diFerent laxative or dose, we would have combined them against
the placebo arm to look at the eFect of the type of laxative rather
than an individual drug.
If there had been heterogeneity between trials looking at diFerent
types of laxative regimen, we planned to carry out a subgroup
analysis to look at the eFect of individual drugs (Subgroup analysis
and investigation of heterogeneity).
Dealing with missing data
We attempted to request additional data from the trial author(s) if
there were insuFicient data in the published paper or uncertainty
about data we were able to extract from the included trial.
We planned to undertake an ITT analysis wherever possible
throughout the review.
We also planned to assess the extent to which trial authors have
employed an ITT analysis and we planned to report the numbers
of participants who dropped out of each arm of the trial, where
possible.
Where data were incomplete but partially available we planned to
use the last available measurement to determine eFectiveness.
Assessment of heterogeneity
If we had included trials reporting the same outcomes which we
were able to include in a meta-analysis, we planned to assess the
level of heterogeneity using the I2 statistic. We intended to look at
the overlap of the CIs on the forest plots to gauge the significance
of the I2 value.
We planned to base our definitions of diFerent levels of
heterogeneity on those described in the Cochrane Handbook for
Systematic Reviews of Interventions:
• low (might not be important) - 0% to 40%;• moderate - 30% to 60%;• substantial - 50% to 90%; and• considerable - 75% to 100%.
The Cochrane Handbook for Systematic Reviews of Interventions
states that this is a rough guide because the importance of
inconsistency depends on several factors (Deeks 2011).
Assessment of reporting biases
Where we had been able to include at least 10 trials, we planned
to generate a funnel plot to attempt to identify any publication
bias in the included trials (Sterne 2011). We also planned to
identify any selective reporting in the included publications, by
comparing the trial protocols with the final papers and by careful
examination of the trial publications and consideration of reporting
of both positive and negative eFects of the intervention. Where trial
protocols were not available, we planned to compare the outcomes
reported in the results section against the methods section of
the paper. We planned to extract information on the sponsors,
sources of funding and competing interests of the authors to
determine the role of external bias being introduced. To minimise
publication bias, we planned to search trial registries and contact
pharmaceutical companies for unpublished data. For the included
trial in the review, we did not have access to the protocol, so
compared the methods section with the results section. We were
also able to gather limited information sources of support for the
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trial, but did not on sources of funding or competing interests. We
searched trial registries for unpublished data on the included trial,
but could not find additional data.
Data synthesis
We were not able to combine trials in a meta-analysis, but if we
are able to do so in future updates of this review we will use
the data from the selected trials to generate forest plots using
the Review Manager soNware (RevMan 2014). We will carry out an
initial combined analysis of all types of laxative agent) followed
by separate meta-analyses for diFerent groups of laxative agents
(e.g. osmotic laxatives, stimulants and those with a combined
mechanism of action) and mucolytics. We will examine the level of
heterogeneity to determine which type of analysis model to use. If
there is low heterogeneity (less than 40%) then we will use a fixed-
eFect model and if the I2 statistic is greater than 40% then we will
use a random-eFects model to summarise the data.
Subgroup analysis and investigation of heterogeneity
In future, if there is greater than 40% heterogeneity among the
included trials, we will undertake subgroup analyses to look at the
following:
• children (18 years and under) versus adults;• type of laxative (osmotic agent (e.g. lactulose) versus stimulant
laxative regimes (e.g. senna) versus mucolytic (e.g. N-
acetylcysteine));• single regimens versus combined regimens (e.g. lactulose and
senna);• eFectiveness of regimen in preventing complete versus
incomplete DIOS* (Houwen 2010).
*The following definitions of complete and incomplete DIOS are
taken from (Houwen 2010).
1. Complete intestinal obstruction as evidenced by vomiting of
bilious material and/or fluid levels in small intestine on an
abdominal radiography.
2. Faecal mass in ileo-caecum.
3. Abdominal pain or distension (or both).
Complete DIOS is defined as when all three of the above criteria are
present, whereas incomplete or impending DIOS is defined as only
the second and third criteria being present.
Sensitivity analysis
If we are able to perform a meta-analysis in future updates, we will
carry out sensitivity analyses to look at the eFect of the risk of bias
findings. We will look at the eFect of adding in and taking out trials
where there is high risk of bias. We will also attempt to examine the
eFect of cross-over trials on the results by carrying out a sensitivity
analysis to include and exclude them.
Summary of findings table
We reported summary of findings information for the comparison
of cisapride versus placebo. In future updates we will present a
separate table for each treatment comparison, i.e. laxative agents
versus control, placebo or alternate regimens. In the summary
of findings table we assess our chosen outcomes: prevention of
complete or incomplete DIOS, adverse events, hospitalisation for
any cause, hospitalisation for DIOS, QoL, symptom score, and
tolerability.
For each outcome we planned to report the illustrative risk with
and without the intervention, magnitude of eFect (RR or MD),
numbers of trials and participants addressing each outcome and
a grade of the overall quality of the body of evidence using
the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) with comments (Schunemann 2006). We report
the available data and where no data for individual outcomes were
available, we state this in the table.
R E S U L T S
Description of studies
Results of the search
Of the 2631 papers (aNer 588 duplicates were removed) identified
by initial searches, we found eight potentially eligible trials for
inclusion. Of these, one trial was included and seven were excluded.
The PRISMA flow diagram illustrates this process (Figure 1).
Included studies
The included trial (n = 17) was available as an abstract and
full text (Koletzko 1990). See the tables for more information
(Characteristics of included studies).
Trial design
The trial was a randomised, double-blind, placebo-controlled
cross-over trial based at a single centre in Toronto, Canada
(Koletzko 1990).
The duration of the trial was 12 months. The participants were
randomised into two groups to take either the placebo or active
drug (cisapride) and then swapped to the other treatment group
aNer six months. The trial accounted for any potential carry-
over treatment eFect of the active drug by analysing the data
in two ways. Measurements were recorded twice for each six-
month period, once every three months. Firstly, investigators took
an average of the two measurements, they then discarded the
measurements from the first three months, to account for any
cumulative eFect of the drug.
Participant characteristics
In terms of the inclusion criteria, the trial required participants
to have a diagnosis of CF and to have had one or more episodes
of DIOS in the preceding 12 months. The trial excluded pregnant
participants, those with current gastrointestinal obstruction and
with serious cardiovascular, neurological, renal or hepatic disease.
Participants with other causes of abdominal pain e.g. peptic ulcer
disease and inflammatory bowel disease were also excluded, as
were those who regularly used metoclopramide, domperidone or
an anticholinergic drug.
There were 17 participants randomised, 12 males and five females.
The recruiting age was not specified, but the mean (range)
age in years of participants was 21.0 (12.9 to 34.9) years. The
baseline characteristics for participants were stated; there were no
significant diFerences in the clinical characteristics between them
at the start of each treatment period.
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Intervention
Participants weighing between 40 kg and 50 kg received 7.5 mg of
either placebo or cisapride three times per day and those weighing
over 50 kg received 10 mg of either placebo or cisapride three times
per day.
Outcomes
The radiological diagnosis of DIOS was measured in the trial using
supine abdominal radiographs. Participants were interviewed for
adverse eFects and also reported any gastrointestinal and global
symptoms, with the use of scoring systems. Other outcomes
included the number of participants requiring therapy for DIOS and
stool weight.
Outcomes reported in the trial but not presented in this
review included anthropometric measurements (e.g. mid-arm
circumference, skin fold thickness), frequency of pulmonary
infections, pulmonary function (% FEV1), nutritional and calorie
intake, routine laboratory tests (e.g. urinalysis, complete blood
count) and number of hospital admissions.
Excluded studies
We excluded seven trials, please see the tables for more
information (Characteristics of excluded studies).
Five trials were excluded because the active drug was not used to
prevent DIOS and therefore reported irrelevant outcomes. In four
of these, N-acetylcysteine was used as a mucolytic for lung disease
in CF, rather than for the prevention of DIOS (Baran 1980; Dietzsch
1980; Gotz 1980; Howatt 1966). In the fiNh trial, N-acetylcysteine
was used to improve malabsorption in CF rather than for the
prevention of DIOS (Mitchell 1981). A further trial was excluded
because the intervention was for the treatment rather than the
prevention of DIOS (Dalzell 1992). The final trial was excluded
because it was not randomised (O'Brien 2011).
Risk of bias in included studies
The risk of bias summary is shown in Figure 2, please also see the
risk of bias table (Characteristics of included studies).
 
Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Allocation
The trial stated that participants were randomly allocated to start
treatment with either cisapride or placebo, but did not specify how
the sequence was generated or the method used for concealment
of allocation. We therefore ranked the study as having an unclear
risk of bias for these categories.
Blinding
Participants and personnel were blinded and the placebo was
identical in taste and appearance to cisapride. For this category, we
ranked the trial as having a low risk of bias.
For the blinding of outcome assessors, the overall risk of bias
was unclear. Only three outcomes stated that the investigators
were blinded. The first of these was gastrointestinal symptom
scores, where the blinded participants acted as their own
assessors. Second was for the assessment of supine abdominal
radiographs, where a paediatric radiologist judged these in
a blind fashion. Third was for the assessment of nutritional
intake and stool collection, where the blinded participants
recorded their own intake and investigators also worked in a
blind fashion. For the other outcomes, the risk of bias was
unclear. Although blinded participants scored their own global
symptoms, physicians assessed them too and we could not
make the assumption that the physicians were blinded. There
was no mention of blinding for the other outcomes in the trial:
anthropometric measurements, number of hospital admissions,
pulmonary function and frequency of pulmonary infections,
laboratory tests, abdominal circumference and intestinal lavage
therapy.
Incomplete outcome data
There were no missing data for gastrointestinal symptom scores
and global symptom scores, both of which were outcomes included
in the review. However, adverse eFects, number of hospital
admissions and radiological signs of DIOS (also outcomes included
in the review) had missing numerical data, despite the investigators
stating that they had been measured. For this reason, we ranked
this category as having an unclear risk of bias.
Outcomes not included in the review that also had missing
numerical data were anthropometric measurements, pulmonary
function, frequency of pulmonary exacerbations and laboratory
values. For nutritional intake and stool losses, only 10 out of 17
participants were represented in the results. This was because
three participants had refused to perform quantitative food intake
protocols and stool collections and four participants were excluded
due to incomplete or inaccurate food records or stool collections.
Although the investigators gave reasons for the missing data, there
was no mention of an ITT analysis.
Selective reporting
We did not have access to the protocol, so could not compare the
list of outcomes in the protocol with the results reported in the trial.
However, we compared the outcomes listed in the methods section
with the outcomes reported in the results section.
The investigators stated that they would calculate the diFerence
in weight and percentage of ideal weight for height during the
two periods, using t tests for comparison. However, these changes
and results of t tests were not reported in the results. Pulmonary
function testing and radiological findings were measured at
baseline and aNer six months, but the results were unreported.
Anthropometric measurements (e.g. mid-arm circumference and
skin fold thickness), physical examination findings, number of
hospital admissions and frequency of pulmonary infections
were measured every three months but insuFiciently reported.
Laboratory test results (blood and urine analysis) were also
measured but not reported.
Due to multiple incidences of selective reporting, we ranked the
trial as having a high risk of bias for this category.
Other potential sources of bias
There was insuFicient information to judge whether there was a
risk of bias from other sources. In terms of publication bias, the
pharmaceutical company, Janssen Pharmaceutica Incorporated,
supported the trial. There was no evidence to suggest that they had
any part in sponsorship or funding but this was not explicitly stated.
There was also no indication to suggest conflicts of interest from the
authors but again, this was not explicitly stated. Due to insuFicient
information regarding other sources of bias in the trial, we rated this
category as having an unclear risk of bias.
E5ects of interventions
See: Summary of findings for the main comparison Cisapride
compared to placebo for preventing distal intestinal obstruction
syndrome (DIOS) in cystic fibrosis
Oral cisapride versus placebo
Please also see Summary of findings for the main comparison.
Primary outcomes
1. Complete or incomplete DIOS
We pre-specified that this review outcome was to be diagnosed
either clinically (e.g. abdominal masses, or distension or pain) or
radiologically (e.g. dilated bowel or faecal mass). The radiological
diagnosis of DIOS was measured in the included trial using a scoring
system for the total radiological severity and severity of each
criterion (e.g. degree and distribution of faecal retention, presence
of bubbly granularity in the right iliac fossa, degree of small bowel
dilatation and nodularity of the intestinal mucosa). However, the
numerical data were not reported in the results. The investigators
stated that there was no significant diFerence between cisapride
and placebo (very low-quality evidence) (Koletzko 1990).
2. Adverse e5ects from treatment
Participants were interviewed for adverse eFects every three
months. The trial reported that no adverse eFects were noted (very
low-quality evidence) (Koletzko 1990).
Secondary outcomes
1. Time to hospital admission
This outcome was not assessed or reported in the trial either for all
causes or due to DIOS (Koletzko 1990).
2. Participant-reported QoL scores
This outcome was not assessed or reported in the trial (Koletzko
1990).
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3. Participant-reported symptom scores
Two diFerent symptom scores were assessed and reported by
participants in this trial: gastrointestinal symptoms and global
symptoms.
For gastrointestinal symptoms, a lower score signified a better
result. Participants scored the severity and frequency of 10 diFerent
gastrointestinal symptoms and total gastrointestinal symptoms
at three-monthly intervals. The trial reported results for a six-
month period, where the scores ranged from 2 to 20 for individual
symptoms and 20 to 100 for the total gastrointestinal symptom
score (Koletzko 1990).
Due to the way the data were presented, we calculated the MD
and standard error (SE) in order to analyse the average symptom
score using the generic inverse variance (GIV). We used the fixed-
eFect model because there was a single trial in the review. The
total gastrointestinal symptom score was statistically significant in
favour of cisapride over the placebo at six months, MD -7.60 (95%
CI -14.73 to -0.47) (very low-quality evidence) (Analysis 1.1).
Individual symptom scores of interest were abdominal distension
and abdominal pain, as they related to the symptoms of DIOS.
There was no significant diFerence between cisapride and placebo
for abdominal pain or abdominal distension at six months (very
low-quality evidence). Abdominal pain showed a MD of -0.4 (95% CI
-2.05 to 1.25) (Analysis 1.2) and abdominal distension showed a MD
of -0.90 (95% CI -2.39 to 0.59) (Analysis 1.3).
Participants also recorded global symptom scores at the end of
each six-month period (i.e. aNer the full course of either cisapride
or placebo). The data were reported as the number of participants
who fell into three categories: those who felt better, the same or
worse with the treatment. Due to the way in which the data were
reported, we were unable to measure this outcome as continuous
or dichotomous. We presented the data in a simple table on to show
the numbers of participants for each category. The trial reported
that the results favoured cisapride and were statistically significant
(P < 0.05) (Table 1).
4. Tolerability
This outcome was not assessed or reported in the trial (Koletzko
1990).
D I S C U S S I O N
Summary of main results
There was only one trial included in this review comparing cisapride
to placebo for the prevention of DIOS (Koletzko 1990). There
were no significant diFerences between cisapride and placebo for
radiological diagnosis of DIOS and no side eFects noted in either
group. The included trial did not report on hospital admissions.
The results found that cisapride improved the total gastrointestinal
symptoms for participants during the trial period. Participants
reported generally feeling better when taking cisapride and those
with worse symptom scores benefited most from the drug. There
were no significant diFerences between cisapride and placebo for
individual symptom scores that were relevant to the review, such
as abdominal distension and abdominal pain.
Overall completeness and applicability of evidence
As there was only one comparison containing one trial in the review
(cisapride versus placebo), we could not perform a meta-analysis of
the data and we were also unable compare the relative eFicacies,
safety and adverse eFects of diFerent laxative agents as we had
intended. The evidence for preventing DIOS is only based on one
low-quality trial that was conducted nearly 30 years ago with a drug
that can no longer be prescribed in several countries, including
the UK (Ferriman 2000). Therefore, the findings are very limited,
irrelevant and largely inapplicable, demonstrating the huge lack of
evidence for the prevention of DIOS in CF.
Outcome measures
We were unable to report several important outcome measures that
we had specified in the protocol. Our primary outcome (diagnosis
of complete or incomplete DIOS) was not fully reported by the
investigators in a way that allowed us to analyse the data. The trial
also stated that there were no adverse eFects from treatment (our
second primary outcome), but did not expand on this. Furthermore,
the trial failed to assess most of our secondary outcomes, such
as time to hospital admission, participant-reported QoL scores
and tolerability. While the trial did report the number of hospital
admissions, they did not report the time to the admission or specify
the reason for each hospital admission. However, the trial did
assess and report participant-reported symptom scores (a further
secondary outcome) using gastrointestinal symptom scores and
global symptom scores.
Participants
The 17 participants (both children and adults) in the included
trial all had a diagnosis of CF; however, the population size was
very small, which limited the precision of the eFect estimates. In
addition, the age range only included older children and young
adults. There were no findings to demonstrate the safety and
eFicacy of cisapride in people with CF of other age ranges.
There were 12 male participants compared to only five female
participants, which could have unfairly aFected the results. In 2016,
Munck found that recurrent DIOS was more common in females
(75% in females compared to 52% in males, P = 0.04) (Munck
2016). If this is the case, the results for the radiological diagnosis of
DIOS may not be accurate, since the data mostly represents male
participants.
Intervention
Cisapride is typically used a gastro-prokinetic agent and it not a
typical laxative that we would have expected to be included in the
review. Furthermore, cisapride has since been withdrawn from the
UK market due to its cardiac side eFects. Therefore, the drug has
no applicability in clinical practice unless it can be re-approved for
license (Ferriman 2000).
Quality of the evidence
The summary of findings table provides information about the
quality of evidence in the review; the quality of evidence of the
included trial is very low (Summary of findings for the main
comparison).
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Strengths
The design of a cross-over trial means that participants act as
their own controls, which eliminates clinical diFerences between
the two treatment arms. The investigators on the included trial
also considered and eliminated the potential carry-over treatment
eFect that could occur with this trial design. As the trial measured
the mean and SD for both the active drug and placebo, we were
able to carry out a paired analysis using the GIV method. Certain
domains of the risk of bias tool demonstrated high-quality trial
design, such as the blinding of participants and personnel. Some
outcomes also reported blinding of the assessors, e.g. supine
abdominal radiography.
Weaknesses
There was only one included trial with a small number of
participants, which led us to downgrade the evidence one level for
precision. The trial was also conducted almost 30 years ago, so its
results have limited relevance today. We could not assess the level
of inconsistency in the review; there was only one trial included and
therefore it was not possible to assess heterogeneity.
The included trial was judged to have an unclear risk of bias across
most of the domains, mainly because the report did not provide
suFicient information for an assessment. The most prominent
areas of unclear bias were: random sequence generation, allocation
concealment and incomplete outcome data.
For the outcomes presented in the summary of findings table, we
downgraded the evidence quality for unclear methods in sequence
generation and allocation concealment. There was also a risk
of selective reporting for a number of outcomes including the
radiological diagnosis of DIOS (for which the investigators did not
fully report the results), pulmonary function, nutritional intake and
stool losses (not presented in this review). We could not find a valid
reason for why the investigators fully reported some results but not
others. The trial gave reasons for some missing data and we judged
that it was missing at random, but the investigators did not (to our
knowledge) conduct an intention-to-treat analysis. Consequently,
there was a high risk of selective reporting bias across the whole
trial.
We were unable to produce a funnel plot to test for publication
bias because we only included one trial in the review. We could not
assume that one trial meant that there was no risk of publication
bias, but equally did not strongly suspect this. We therefore rated
publication bias as 'undetected'.
Potential biases in the review process
During the process of trial screening, data collection and data
extraction, there was a low risk of bias. Two authors independently
screened the trials and resolved any disputes mainly by discussion,
but with the third author acting as an external arbiter if needed.
Agreements and disagreements with other studies or
reviews
The included trial was published in 1990 when cisapride was a
fully licensed drug in the UK (Koletzko 1990). It was commonly
used to treat gastric and digestive disorders in children and adults.
However in July 2000, the Medicines Control Agency suspended
the use of cisapride in the UK due to the rare but serious cardiac
eFects associated with the drug (Ferriman 2000). These eFects were
associated with ventricular arrhythmias and in some cases, sudden
death. Between 1988 and 2000, the UK received reports of 60
adverse cardiovascular reactions of the drug, five of which resulted
in death. Worldwide, there were 125 fatal reactions to cisapride,
which led to many other countries suspending the marketing for
the drug, e.g. USA, Canada and Germany.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The results of this Cochrane Review signal that there is no evidence-
base for the prevention of distal intestinal obstruction syndrome
(DIOS) in clinical practice. Conversely, there are a high number
of randomised controlled trials on the respiratory complications
in cystic fibrosis (CF). This is likely the case because people
with CF predominantly suFer from respiratory complications and
are most likely to die from respiratory failure. However, many
complications in CF aFect the overall health of the individual. If
gastrointestinal problems such as constipation and DIOS are not
managed eFectively, they may worsen the individual's quality of
life, nutritional status, mobility, and ultimately make them more
susceptible to respiratory infections. It is therefore imperative that
these problems are placed at a higher level of importance.
Implications for research
As there was only one low-quality, cross-over trial eligible for
inclusion in this Cochrane Review, it is evident that there is a
great need for more research in this area. Future trials should
include larger numbers of participants for more precision and
be designed as randomised placebo-controlled trials in order to
provide robust evidence. There is reliable evidence to support the
use of patient-reported outcome measures (PROMs) in healthcare.
A 2013 systematic review demonstrated that eFective PROMs
improve patient-provider communication, patient satisfaction,
the monitoring of treatment response and the detection of
unrecognised problems (Chen 2013). In particular, with very little
research on gastrointestinal problems in CF, there is no consensus
for the best outcome measures to use in gastrointestinal-focused
trials. This was outlined in the 2017 James Lind Alliance Priority
Setting Partnership in CF, a partnership between people with
CF and healthcare providers (Rowbotham 2017). The partnership
reached a consensus for a list of the 10 most important research
priorities in CF, the second of which was "How can we relieve
gastro-intestinal (GI) symptoms, such as stomach pain, bloating
and nausea in people with CF?". This research priority emphasises
the lack of PROMs for gastrointestinal problems in CF. Any future
research would be significantly improved by ensuring agreed
consensus on validated gastrointestinal outcome measures for
symptoms.
The pathophysiology of DIOS is multifactorial. It is highly likely
that there will be more than one successful strategy for preventing
it. These include prokinetics, mucolytic agents and drugs or
treatments which restore CFTR function.
Following on from the limited findings of this review, it would
be very interesting to look at the role of prokinetic agents
for preventing or treating DIOS. Although cisapride has been
removed from the UK drug market amongst others, there are
many other types of prokinetic agents such as domperidone and
metoclopramide, as well as antibiotics with prokinetic properties
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such as erythromycin and azithromycin. Azithromycin is commonly
used for respiratory complications in CF, so it would be interesting
to see whether the incidence of DIOS in people taking azithromycin
is significantly diFerent to those not taking it. An observational
study using data from the UK CF Data Registry could help obtain
this information. There are various factors that may aFect the
incidence of DIOS; those who take regular azithromycin arguably
have a lower standard of health and may be more likely to suFer
from gastrointestinal complications, such as DIOS. However, these
types of factors could be accounted for in subgroup analyses,
e.g. grouping individuals according to their lung function (force
expiratory volume in one second (FEV1) % predicted). In summary,
the lack of evidence on this subject has opened up various avenues
for further research. ANer this Cochrane Review has identified the
potential use of prokinetic agents for the prevention of DIOS (albeit
in a very limited way), we believe the next logical step is to further
investigate their role in the management of DIOS.
We have not found evidence of mucolytic agents used for the
prevention of DIOS, but we know that these are used in clinical
practice. It would be helpful to look at the eFectiveness and
safety of mucolytic agents in a randomised controlled trial for the
prevention of DIOS.
CFTR potentiators and gene therapies are a growing area of CF
medicine. IvacaNor (a CFTR potentiator) is already licensed for
the G551D mutation in CF due to its significant and sustained
improvements on lung function (Ramsey 2011). The combination
of lumacaNor and ivacaNor (marketed as Orkambi®) has also shown
significant improvements in lung function for the most common
mutation, homozygous Phe508del (US FDA 2016). It it likely that
the gastrointestinal symptoms will also be improved with these
agents, as they target the CFTR channel itself. They have an
impact on CFTR in the pancreatic ducts, hence reducing mucus
viscosity and overproduction. These agents may therefore have a
positive impact on the rate of DIOS episodes. Newer gene therapies,
specifically lentiviral vector gene therapy, have also shown promise
in earlier studies (Alton 2017). It would be beneficial to conduct an
observational study to further investigate the role of these agents
in the prevention of DIOS.
Aside from exploring the use of these diFerent agents
(prokinetic laxatives, prosecretory laxatives, mucolytics and CFTR
potentiators) in individual trials, it would be more robust to conduct
a randomised controlled trial that could compare the diFerent
types of laxatives and CFTR potentiators. It would compare current
regimens, and then standard of care to newly-released agents,
either novel laxatives (prosecretory or prokinetic) or CFTR-targeted
medicines, for the prevention of DIOS.
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Characteristics of included studies [ordered by study ID]
 
Methods Study design: randomised controlled trial, double-blind placebo-controlled
Study grouping: cross-over, each arm lasted for 6 months
Carry-over treatment effect accounted for: yes. Measurements were recorded twice for each 6-
month period. Investigators took an average of the 2 measurements, they then discarded the measure-
ments from the first 3 months, to account for any cumulative effect of the drug. There was no formal
washout period
Participants Inclusion criteria: diagnosis of CF (by sweat test > 60 mmol/L); 1 or more episodes of DIOS in preced-
ing 12 months (based on clinical or radiological evidence and on successful treatment with intestinal
lavage, oral N-acetylcysteine or both)
Exclusion criteria: peptic ulcer disease, inflammatory bowel disease, anatomic intestinal obstruction,
serious cardiovascular, neurological, renal or hepatic disease, severe pulmonary dysfunction (maximal
mid-expiration flow rate < 25% normal) pregnancy, regular use of metoclopramide, domperidone or
anticholinergic drug
Pre-treatment: no significant differences in the clinical characteristics of 2 groups (cross-over)
Baseline characteristics
Age, mean (SD), range: 21.0 (5.9) years, 12.9 to 34.9 years old
Mean (SD) duration of DIOS symptoms: 4.2 (3.1) years
Mean (SD) height percentile: 40.6 (26.3)
Mean (SD) weight percentile: 40.3 (23.2)
Mean (SD) weight for height: 100.3 (9.5) % of ideal
Mean (SD) FVC (% predicted): 80.9 (23.4)%
Mean (SD) FEV1 (% predicted): 78.2 (28.1)%
Interventions Cisapride: oral tablets 7.5 mg 3 times daily (before meals) for participants weighing between 40 kg and
50 kg, 10 mg 3 times daily (before meals) for participants weighing over 50 kg
Placebo (identical in appearance to active treatment): oral tablets 7.5 mg 3 times daily (before meals)
for participants weighing between 40 kg and 50 kg, 10 mg 3 times daily (before meals) for participants
weighing over 50 kg
Outcomes Gastrointestinal symptoms: a total of 10 symptoms scored 1 to 10 (heartburn, flatulence, regurgita-
tion, fullness, abdominal distension, abdominal pain, diarrhoea, nausea, vomiting, anorexia) and also
added to give a total score (20 to 100) where a lower score is better; severity (none, not limiting daily ac-
tivities, limits daily activities, daily activities not possible) and frequency (never, less than once a week,
more than once a week or daily) of symptoms recorded and accounted for in final score for each item
Anthrompometric measurements: mid-arm circumference; skin fold thickness; change in weight; ab-
dominal circumference
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Alteration in global symptoms: measured by both physician and participant, from 'worse' to 'symp-
tom-free' using scores from -1 to +3 (higher is better)
Pulmonary function: FEV1 % predicted, frequency of pulmonary exacerbations, number of hospital
admissions
Nutrient intake: calories (kcal/day), fat (mmol/day)
Stool composition: stool weight (g/day), faecal water content (%), faecal fat (%), calories malabsorbed
(%), faecal bile acids (mmol/day), faecal chymotrypsin (10 x 300 units/day)
Supine abdominal radiography
Intestinal lavage therapy
Identification Sponsorship source: supported by Janssen Pharmaeutica Inc., Canada. No sponsorship mentioned
Country: Canada
Setting: single centre (tertiary centre) at the University of Toronto and the research institute at the
Hospital for Sick Children, Toronto
Comments: approved by the human subjects review committee of the Hospital for Sick Children,
Toronto. Janssen Pharmaceutica supplied cisapride and placebo tablets
Contact author's name: Sibylle Koletzko
Institution: Children's Hospital, Heinrich Heine University, Dusseldorf, Federal Republic of Germany
Email: Sibylle.Koletzko@med.uni-muenchen.de
Address: Lindwurmstraße 4, 80337 München, Germany
The authors did not declare any conflicts of interest
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Random allocation stated but no specific sequence generation methodology
described.
Allocation concealment
(selection bias)
Unclear risk No method described for concealment of allocation.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk "Double-blind" trial. Placebo tablets were identical in taste and appearance to
cisapride.
Blinding of outcome as-
sessment (detection bias)
Unclear risk Only 3 outcomes stated that the investigators were blinded.
1. Gastrointestinal symptom scores - the blinded participants acted as their
own assessors.
2. Assessment of supine abdominal radiographs - a paediatric radiologist
judged these in a blind fashion.
3. Assessment of nutritional intake and stool collection - the blinded partici-
pants recorded their own intake and investigators also worked in a blind fash-
ion.
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Although blinded participants scored their own global symptoms, physicians
assessed them too and we could not make the assumption that the physicians
were blinded.
There was no mention of blinding for the other outcomes: anthropometric
measurements, number of hospital admissions, pulmonary function and fre-
quency of pulmonary infections, laboratory tests, abdominal circumference
and intestinal lavage therapy.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No missing data and outcomes fully reported: gastrointestinal symptom
scores, global symptom scores and intestinal lavage therapy
Insufficient information to judge whether outcome data are missing: anthro-
pometric measurements, adverse effects, pulmonary function, frequency of
pulmonary exacerbations, number of hospital admissions, radiological signs
of DIOS and laboratory values
Data missing: for nutritional intake and stool losses, only present data for
10/17 participants, reasons given for missing data but this would have had a
big impact on the effect size, since the sample size was small anyway; no men-
tion of ITT analysis, no mention of treating per protocol
Selective reporting (re-
porting bias)
High risk No access to trial protocol so not possible to compare planned outcomes to
outcomes reported in paper.
Anthropometric measurements: stated in the methods section that "at the end
of each treatment period, difference weight and percentage of ideal weight for
height, as well as the difference in weight change during the two periods, were
compared by means of t tests", however, these changes and results of t tests
were not specifically reported in the results, incomplete report means it can
not be entered into a meta- analysis.
Pulmonary function testing and X-ray findings: although supposed to be mea-
sured "at the end of baseline and 6 month periods" were reported incomplete-
ly so cannot be entered into a meta-analysis.
Cisapride levels: in the methods section, it specified that they would deter-
mine cisapride levels "at the end of baseline and 6 month periods" but this
was not reported in the results.
Number of hospital admissions: specified as an outcome measure in the meth-
ods section, but not reported in the results.
Laboratory test results (blood and urine analysis): incompletely reported so
that they could not be entered into a meta-analysis.
Other bias Unclear risk None known, but cannot be sure, there is no known sponsorship source but
the trial was described as being supported by Janssen Pharmaceuticals.
Koletzko 1990  (Continued)
CF: cystic fibrosis
DIOS: distal intestinal obstruction syndrome
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
ITT: intention-to-treat analysis
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Study Reason for exclusion
Baran 1980 Inappropriate indication: N-acetylcysteine used for respiratory complications rather than for pre-
venting DIOS
Dalzell 1992 Inappropriate interventions: pancreatic enzyme therapy used for treatment of DIOS instead of pre-
vention of DIOS
Dietzsch 1980 Inappropriate indication: N-acetylcysteine used for respiratory complications rather than for pre-
venting DIOS
Gotz 1980 Inappropriate indication: N-acetylcysteine used for respiratory complications rather than for pre-
venting DIOS
Howatt 1966 Inappropriate indication: N-acetylcysteine used for respiratory complications rather than for pre-
venting DIOS
Mitchell 1981 Inappropriate indication: N-acetylcysteine used for malabsorption in CF rather than for preventing
DIOS
O'Brien 2011 Non-randomised and open-label design
CF: cystic fibrosis
DIOS: distal intestinal obstruction syndrome
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Comparison 1.   Cisapride versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Total gastrointestinal symptoms 1   Mean Difference (Fixed, 95% CI) Totals not selected
1.1 At 6 months 1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Abdominal pain 1   Mean Difference (Fixed, 95% CI) Totals not selected
2.1 At 6 months 1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Abdominal distension 1   Mean Difference (Fixed, 95% CI) Totals not selected
3.1 At 6 months 1   Mean Difference (Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Cisapride versus placebo, Outcome 1 Total gastrointestinal symptoms.
Study or subgroup Cisapride Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.1.1 At 6 months  
Favours cisapride 2010-20 -10 0 Favours placebo
Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
24
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study or subgroup Cisapride Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
Koletzko 1990 17 17 -7.6 (3.64) -7.6[-14.73,-0.47]
Favours cisapride 2010-20 -10 0 Favours placebo
 
 
Analysis 1.2.   Comparison 1 Cisapride versus placebo, Outcome 2 Abdominal pain.
Study or subgroup Cisapride Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.2.1 At 6 months  
Koletzko 1990 17 17 -0.4 (0.841) -0.4[-2.05,1.25]
Favours cisapride 42-4 -2 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Cisapride versus placebo, Outcome 3 Abdominal distension.
Study or subgroup Cisapride Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Fixed, 95% CI IV, Fixed, 95% CI
1.3.1 At 6 months  
Koletzko 1990 17 17 -0.9 (0.762) -0.9[-2.39,0.59]
Favours cisapride 42-4 -2 0 Favours placebo
 
 
A D D I T I O N A L   T A B L E S
 
Intervention Total number of participants Felt better Felt the same Felt worse
Cisapride 17 12 2 3
Placebo 17 3 2 12
Table 1.   Alterations in global symptoms 
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
Database/Resource Strategy
Cochrane Central Register of
Controlled Trials (CENTRAL)
#1 Cystic Fibrosis [MeSH descriptor]
#2 cystic fibrosis:ti,ab
#3 fibrocystic near/10 disease near/10 pancreas
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#4 mucoviscidos*:ti,ab
#5 cystic* near/10 fibros*:ti,ab
#6 #1 or #2 or #3 or #4 or #5
#7 distal intestinal obstruction syndrome*:ti,ab
#8 dios or mie:ti,ab
#9 Intestinal Obstruction [MeSH descriptor]
#10 meconium ileus equivalent:ti,ab
#11 faecal near/3 (obstruction or impact*):ti,ab
#12 Constipation [MeSH descriptor]
#13 constipat*:ti,ab
#14 laxative*:ti,ab
#15 Laxatives [MeSH descriptor]
#16 lactulose:ti,ab
#17 Lactulose [MeSH descriptor]
#18 (macrogol or polyethylene glycol*):ti,ab
#19 Polyethylene Glycols [MeSH descriptor]
#20 movicol:ti,ab
#21 klean*:ti,ab
#22 diatriozate:ti,ab
#23 gastrografin:ti,ab
#24 senna:ti,ab
#25 docusate:ti,ab
#26 picosulfate:ti,ab
#27 acetylcysteine or fibrol:ti,ab
#28 parvolex:ti,ab
#29 fibre:ti,ab
#30 picosulphate:ti,ab
#31 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21
or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 #30
#32 #6 and #31
MEDLINE Ovid (1946 onwards) 1. Cystic Fibrosis/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
  (Continued)
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5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. "distal intestinal obstruction syndrome*".tw.
8. (dios or mie).tw.
9. Intestinal Obstruction/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
12. Constipation/
13. "constipat*".tw.
14. "laxative*".tw.
15. Laxatives/
16. lactulose.tw. or Lactulose/
17. (macrogol or polyethylene glycol*).tw. or Polyethylene Glycols/
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or
25 or 26 or 27 or 28
30. 6 and 29
Embase Ovid (1974 onwards) 1. CYSTIC FIBROSIS/
2. cystic fibrosis.tw.
3. (fibrocystic adj10 disease adj10 pancreas).tw.
4. mucoviscidos$.tw.
5. (cystic$ adj10 fibros$).tw.
6. 1 or 2 or 3 or 4 or 5
7. "distal intestinal obstruction syndrome*".tw.
  (Continued)
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8. (dios or mie).tw.
9. INTESTINE OBSTRUCTION/
10. meconium ileus equivalent.tw.
11. (faecal adj3 (obstruction or impact*)).tw.
12. CONSTIPATION/
13. "constipat*".tw.
14. "laxative*".tw.
15. LAXATIVE/
16. lactulose.tw. or LACTULOSE/
17. (macrogol or polyethylene glycol*).mp,hw.
18. movicol.tw.
19. klean*.tw.
20. diatriozate.tw.
21. gastrografin.tw.
22. senna.tw.
23. docusate.tw.
24. bicosulfate.tw.
25. acetylcysteine or fibrol.tw.
26. parvolex.tw.
27. fibre.tw.
28. picosulphate.tw.
29. 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or
25 or 26 or 27 or 28
30. 6 and 29
Clinicaltrials.gov ADVANCED SEARCH
Search 1
Search terms: laxative OR laxatives OR lactulose OR macrogol OR polyethylene OR movicol OR
klean OR diatriozate OR gastrografin OR senna OR docusate OR bicosulfate OR acetylcysteine OR fi-
brol OR parvolex OR picosulphate OR fibre
Study type: Interventional Studies
Conditions: cystic fibrosis
Search 2
Search terms: intestinal OR DIOS OR constipation OR constipated OR faecal OR meconium
Study type: Interventional Studies
Conditions: cystic fibrosis
ISRCTN Registry ADVANCED SEARCH
Condition: cystic fibrosis
WHO ICTRP BASIC SEARCHES
  (Continued)
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Search 1: cystic fibrosis AND intestinal
Search 2: cystic fibrosis AND constipation
Search 3: cystic fibrosis AND faecal
Search 4: cystic fibrosis AND meconium
Search 5: mucoviscidose
ADVANCED SEARCH
Condition: cystic fibrosis
Intervention: laxative OR laxatives OR lactulose OR macrogol OR polyethylene OR movicol OR klean
OR diatriozate OR gastrografin OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol
OR parvolex OR picosulphate OR fibre
Recruitment Status: All
Open Grey (cystic fibrosis OR cf OR mucoviscidos*) AND (intestin* OR constipat* OR faecal OR meconium OR
laxative* OR lactulose OR macrogol OR polyethylene OR movicol OR klean* OR diatriozate OR gas-
trografin OR senna OR docusate OR bicosulfate OR acetylcysteine OR fibrol OR parvolex OR pico-
sulphate OR fibre)
  (Continued)
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Roles and responsibilities
TASK WHO UNDERTOOK THE TASK
Protocol stage: draN the protocol WC
Review stage: select which trials to include (2 + 1 arbiter) JG + WC + FG as arbiter
Review stage: extract data from trials (2 people) JG + WC
Review stage: enter data into RevMan JG
Review stage: carry out the analysis JG + WC
Review stage: interpret the analysis JG + WC
Review stage: draN the final review JG + WC
Update stage: update the review WC
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol, we did not list prokinetic agents as a possible treatment for distal intestinal obstruction syndrome (DIOS). However, we have
now included them in the review because there is evidence in the literature for their role in treating constipation and generally increasing
colonic transit and motility (Boyle 2009; Colombo 2011). As the treatment of constipation is especially important in the prevention of DIOS,
we decided to include them as a possible intervention in this review.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cisapride  [*therapeutic use];  Cystic Fibrosis  [*complications];  Gastrointestinal Agents  [*therapeutic use];  Intestinal Obstruction
 [etiology]  [pathology]  [*prevention & control];  Syndrome
MeSH check words
Adolescent; Adult; Humans
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